Clinical Trials | November 29, 2023
Roche expands hepatitis diagnostics portfolio
Almost 300 million people globally have chronic hepatitis B
Almost 300 million people globally have chronic hepatitis B
Both the India and GCC entities will be operated by separate dedicated management teams
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
